8-KEarnings & ResultsExhibits & Filings

MCKESSON CORP 8-K Report, Financial Results (Sep 22, 2020)

Filed September 22, 2020For Securities:MCK

Summary

McKesson Corporation (MCK) filed an 8-K on September 22, 2020, to furnish investors with supplemental historical financial information. This information is presented under a newly defined four-segment reporting structure: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). These changes are effective from the second quarter of fiscal year 2021 and reflect the company's reorganized operational structure. The retrospective restatement of historical segment data aims to provide investors with a clearer understanding of the company's performance across these new segments. The filing also clarifies that the company has completed its separation from its investment in Change Healthcare LLC, with the financial results of this joint venture being included in the 'Other' category for historical periods presented. While these segment changes do not alter previously reported consolidated financial statements or earnings per share, they are intended to align financial reporting with the company's strategic focus and resource allocation decisions made by its chief operating decision maker.

Key Highlights

  • 1McKesson is restating historical financial data to align with a new four-segment reporting structure: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
  • 2These segment changes are effective for financial reporting commencing in the second quarter of fiscal year 2021.
  • 3The company believes this retrospective segment presentation will enhance investor understanding of performance across its revised operational segments.
  • 4McKesson has completed its separation from the Change Healthcare LLC joint venture.
  • 5The Change Healthcare JV's financial results will be included in the 'Other' category for historical periods presented.
  • 6The segment realignments do not impact previously issued consolidated financial statements or earnings per share.
  • 7The new structure is designed to reflect the company's evolving focus on healthcare industry solutions and strategic resource allocation.

Frequently Asked Questions

McKesson is filing this 8-K to provide investors with supplemental historical financial information that has been restated to reflect a new, four-segment reporting structure. This is a voluntary furnishing of information to help investors understand the company's performance under its revised organizational alignment.

The new reportable segments are: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). These segments reflect how the company's chief operating decision maker allocates resources and assesses performance.

No, the segment changes do not impact previously issued consolidated financial statements or earnings per common share for historical periods. This filing provides supplemental information for comparative purposes under the new structure.

McKesson has completed its separation from its investment in Change Healthcare LLC. The financial results of this joint venture will be included in the 'Other' category for the historical periods being presented in this supplemental information.